Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
JIM CRAMER
Lightning Round Stocks to Buy From Mad Money With Jim Cramer
By Danny Peterson
Feb 17, 2021 8:30 AM EST
PRESS RELEASES
MS In Harmony
By Business Wire
Feb 23, 2021 9:00 AM EST
PRESS RELEASES
Bristol Myers Squibb To Participate In Raymond James Virtual 42nd Annual Institutional Investors Conference
By Business Wire
Feb 23, 2021 6:59 AM EST
PRESS RELEASES
Bristol Myers Squibb And Celgene Issue Notices Of Redemption And Partial Redemption Of Certain Of Their Senior Notes At "Make Whole" Prices
By Business Wire
Feb 22, 2021 6:15 PM EST
JIM CRAMER
Lightning Round Stocks to Buy From Mad Money With Jim Cramer
By Danny Peterson
Feb 17, 2021 8:30 AM EST
INVESTING
Heat Biologics Jumps on Progress With Lung-Cancer Drug
By Tony Owusu
Feb 9, 2021 10:08 AM EST
PRESS RELEASES
Bristol Myers Squibb Receives European Commission Approval For Inrebic® (fedratinib) For Adult Patients With Newly Diagnosed And Previously Treated Myelofibrosis
By Business Wire
Feb 8, 2021 12:12 PM EST
Video
Jim Cramer Looks to Buy Stocks for His Portfolio
Feb 7, 2021 12:00 PM EST
PRESS RELEASES
U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene Maraleucel), A New CAR T Cell Therapy For Adults With Relapsed Or Refractory Large B-cell Lymphoma
By Business Wire
Feb 5, 2021 4:39 PM EST
PRESS RELEASES
Bristol Myers Squibb To Participate In Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day
By Business Wire
Feb 5, 2021 6:59 AM EST
MARKETS
S&P 500 Closes at Record; Stocks Extend Win Streak to Four
By Joseph Woelfel
Feb 4, 2021 4:18 PM EST
INVESTING
Bristol-Myers Flat After Report - Here's the Must-Hold Support Level
By Bret Kenwell
Feb 4, 2021 1:30 PM EST
INVESTING
Merck, Bristol Myers Squibb, PayPal, Apple - Thursday's Premarket Movers
By Vidhi Choudhary
Feb 4, 2021 8:33 AM EST
INVESTING
Bristol-Myers Tops Q4 Earnings Forecast, Boosts 2021 Outlook
By Martin Baccardax
Feb 4, 2021 9:35 AM EST
MARKETS
Stimulus Checks, PayPal, Dogecoin, Merck, Ford - 5 Things You Must Know Thursday
By Joseph Woelfel
Feb 4, 2021 8:31 AM EST
INVESTING
Bristol Myers Gains Rights to Rockefeller's Covid Treatment
By Dan Weil
Feb 3, 2021 11:02 AM EST
PRESS RELEASES
Couvet, Switzerland (Photo: Business Wire)
By Business Wire
Feb 2, 2021 6:59 AM EST
PRESS RELEASES
Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study Showing Superiority Of Deucravacitinib Compared To Placebo And Otezla® (apremilast)
By Business Wire
Feb 2, 2021 6:59 AM EST
PRESS RELEASES
Bristol Myers Squibb Application For Zeposia® (ozanimod) For The Treatment Of Ulcerative Colitis Accepted For Filing With Priority Review By U.S. Food And Drug Administration
By Business Wire
Feb 1, 2021 6:59 AM EST
INVESTING
Dow Futures Rebound, Silver Surges To Seven-Year High As Reddit Retail Army Targets Metals
By Martin Baccardax
Feb 1, 2021 9:10 AM EST
INVESTING
Morning Bell With Jim Cramer: Buy the Dip in Ford After Earnings
By Vidhi Choudhary
Jan 26, 2021 8:55 AM EST
PRESS RELEASES
U.S. Food And Drug Administration Approves OPDIVO® (nivolumab) In Combination With CABOMETYX® (cabozantinib) As First-line Treatment For Patients With Advanced Renal Cell Carcinoma
By Business Wire
Jan 22, 2021 1:18 PM EST
PRESS RELEASES
U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (nivolumab) As Adjuvant Therapy For Patients With Resected Esophageal Or Gastroesophageal Junction Cancer
By Business Wire
Jan 20, 2021 6:59 AM EST
JIM CRAMER
Accentuate the Positive: Cramer's 'Mad Money' Recap (Monday 1/11/21)
By Scott Rutt
Jan 11, 2021 8:27 PM EST
JIM CRAMER
Game Plan: Cramer's 'Mad Money' Recap (Friday 1/8/21)
By Scott Rutt
Jan 8, 2021 8:37 PM EST